Novo Nordisk in stem cell therapy deals

Lund University (Lund, Sweden) and Duke-NUS Medical School (Singapore) each partnered with Novo Nordisk A/S (NYSE:NVO; CSE:NOVO B) and granted the company rights to develop stem cell-based therapies. The therapies are based on Biolaminins from BioLamina AB (Stockholm, Sweden), which are human recombinant laminin cell culture matrices.

The partnership with Lund will focus on Parkinson's disease and the collaboration with Duke-NUS will focus on cardiomyopathy and age-related macular degeneration (AMD). Under the deal with Duke-NUS, Novo will provide research funding for 3-5 years...